All In Biotech

Drug Trial Radar · NCT07229729

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

A Randomized, Open-label, Multicenter Phase II Clinical Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 24, 2025

Primary completion

Oct 2026

Study completion Oct 2029

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • SHR-A2102Drug

    SHR-A2102.

  • AdebrelimabDrug

    Adebrelimab.

  • PaclitaxelDrug

    Paclitaxel.

  • CarboplatinDrug

    Carboplatin.

  • Alomnertinib MesilateDrug

    Alomnertinib Mesilate.

  • Furmonertini MesilateDrug

    Furmonertini Mesilate.

  • Osimertinib MesylateDrug

    Osimertinib Mesylate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathology complete response (pCR)Time frame: Up to approximately 20 weeks.
  2. 18-month event free rateTime frame: Up to approximately 18 months.
  3. 2-years disease free rateTime frame: Up to approximately 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.